Publication Date:
2015-04-22
Description:
by Rui Chen, Jinchuan Yan, Peijing Liu, Zhongqun Wang Background Inflammation is a common feature in patients with type 2 diabetes mellitus (T 2 DM). This meta-analysis aimed to assess the influence of thiazolidinedione (TZD) therapy on the circulating levels of inflammatory markers in patients with T 2 DM. Methods and Results We searched the databases Medline, Embase, ScienceDirect, Web of Science, SpringerLink, and the Cochrane Library for randomized controlled trials (RCTs) that examined the effects of thiazolidinedione vs. a placebo on patients with T 2 DM. The main outcomes were absolute changes in levels of circulating inflammatory markers. Twenty-seven RCTs were included and data were analyzed using a fixed-effect model or a random-effect model based on heterogeneity. Pooled results indicated that circulating levels of high-sensitivity C reactive protein (hsCRP; SMD = –0.65, 95% CI = –0.98 to –0.32, p 〈 0.01), monocyte chemoattractant protein-1 (MCP-1; WMD = –54.19, 95% CI = –73.86 to –34.52, p 〈 0.01), von Willebrand factor% (vWF%; WMD = –8.18, 95% CI = –13.54 to –2.81, p 0.01), fibrinogen (SMD = –0.26, 95% CI = –0.41 to –0.11, p 〈 0.01) and E-selectin(WMD = –3.57, 95% CI = –5.59 to -1.54, p
Electronic ISSN:
1932-6203
Topics:
Medicine
,
Natural Sciences in General
